Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes

Hany E. Marei(Mansoura University), Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine), Sara Caratelli(National Academies of Sciences, Engineering, and Medicine), Giulia Lanzilli(Istituto di Farmacologia Traslazionale), Tommaso Sconocchia(Istituto di Farmacologia Traslazionale), Mario Roselli(University of Rome Tor Vergata), Thomas Caceci(Carilion Clinic), Carlo Cenciarelli(Istituto di Farmacologia Traslazionale), Roberto Arriga(University of Rome Tor Vergata), Asma Al-Thani(Qatar University), Alessio Ottaviani(Istituto di Farmacologia Traslazionale)
Biochemical Pharmacology
June 7, 2019
10.1016/j.bcp.2019.06.002
Cited by 25

Related Papers

p53 signaling in cancer progression and therapy
|Cancer Cell International|2021|580
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|333
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
|Blood|2003|211
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
|World Journal of Emergency Surgery|2016|198
NK cells and T cells cooperate during the clinical course of colorectal cancer
|OncoImmunology|2014|153